IOM Report Faults Nation's Record of Medical Mistakes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 1
Volume 9
Issue 1

WASHINGTON-An Institute of Medicine (IOM) committee has urged instituting a comprehensive strategy to sharply reduce medical errors that result in needless death and injury. According to an IOM report, one study put the annual number of deaths in the United States from medical mistakes at 44,000 and a second study concluded the toll reached 98,000.

WASHINGTON—An Institute of Medicine (IOM) committee has urged instituting a comprehensive strategy to sharply reduce medical errors that result in needless death and injury. According to an IOM report, one study put the annual number of deaths in the United States from medical mistakes at 44,000 and a second study concluded the toll reached 98,000.

The IOM proposes creating a National Center for Patient Safety, which would be housed in the Agency for Health Care Policy and Research and would act as a clearinghouse for objective information on patient safety. It also recommends creating a mandatory system for public reporting of medical errors, excluding certain information, such as medical mistakes that are collected solely to improve safety and quality and that have no serious consequences,

Further, the committee urged the FDA to increase its attention to public safety through efforts such as eliminating similar-sounding drug names and confusing labels and packaging that foster mistakes; and urged health care organizations to create an environment in which safety holds top priority.

Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Related Content